These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

295 related articles for article (PubMed ID: 34253637)

  • 21. A novel brick for bispecific antibody construction.
    He Y; Ma H; Wang C; Ai Z; Wu Q; Chen H; Lu D
    Proteins; 2023 Aug; 91(8):1065-1076. PubMed ID: 36964928
    [TBL] [Abstract][Full Text] [Related]  

  • 22. A BCMAxCD3 bispecific T cell-engaging antibody demonstrates robust antitumor efficacy similar to that of anti-BCMA CAR T cells.
    DiLillo DJ; Olson K; Mohrs K; Meagher TC; Bray K; Sineshchekova O; Startz T; Kuhnert J; Retter MW; Godin S; Sharma P; Delfino F; Lin J; Smith E; Thurston G; Kirshner JR
    Blood Adv; 2021 Mar; 5(5):1291-1304. PubMed ID: 33651100
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Development of a Target cell-Biologics-Effector cell (TBE) complex-based cell killing model to characterize target cell depletion by T cell redirecting bispecific agents.
    Jiang X; Chen X; Carpenter TJ; Wang J; Zhou R; Davis HM; Heald DL; Wang W
    MAbs; 2018; 10(6):876-889. PubMed ID: 29985776
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Overcoming leukemia heterogeneity by combining T cell engaging bispecific antibodies.
    Hoseini SS; Espinosa-Cotton M; Guo HF; Cheung NV
    J Immunother Cancer; 2020 Nov; 8(2):. PubMed ID: 33239418
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Combination Therapy with Bispecific Antibodies and PD-1 Blockade Enhances the Antitumor Potency of T Cells.
    Chang CH; Wang Y; Li R; Rossi DL; Liu D; Rossi EA; Cardillo TM; Goldenberg DM
    Cancer Res; 2017 Oct; 77(19):5384-5394. PubMed ID: 28819027
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Factors Affecting the Cancer Immunotherapeutic Efficacy of T Cell Bispecific Antibodies and Strategies for Improvement.
    Long M; Mims AS; Li Z
    Immunol Invest; 2022 Nov; 51(8):2176-2214. PubMed ID: 36259611
    [TBL] [Abstract][Full Text] [Related]  

  • 27. The enhanced antitumor activity of bispecific antibody targeting PD-1/PD-L1 signaling.
    Li T; Niu M; Zhou J; Wu K; Yi M
    Cell Commun Signal; 2024 Mar; 22(1):179. PubMed ID: 38475778
    [TBL] [Abstract][Full Text] [Related]  

  • 28. An anti-glypican 3/CD3 bispecific T cell-redirecting antibody for treatment of solid tumors.
    Ishiguro T; Sano Y; Komatsu SI; Kamata-Sakurai M; Kaneko A; Kinoshita Y; Shiraiwa H; Azuma Y; Tsunenari T; Kayukawa Y; Sonobe Y; Ono N; Sakata K; Fujii T; Miyazaki Y; Noguchi M; Endo M; Harada A; Frings W; Fujii E; Nanba E; Narita A; Sakamoto A; Wakabayashi T; Konishi H; Segawa H; Igawa T; Tsushima T; Mutoh H; Nishito Y; Takahashi M; Stewart L; ElGabry E; Kawabe Y; Ishigai M; Chiba S; Aoki M; Hattori K; Nezu J
    Sci Transl Med; 2017 Oct; 9(410):. PubMed ID: 28978751
    [TBL] [Abstract][Full Text] [Related]  

  • 29. A tetravalent bispecific TandAb (CD19/CD3), AFM11, efficiently recruits T cells for the potent lysis of CD19(+) tumor cells.
    Reusch U; Duell J; Ellwanger K; Herbrecht C; Knackmuss SH; Fucek I; Eser M; McAleese F; Molkenthin V; Gall FL; Topp M; Little M; Zhukovsky EA
    MAbs; 2015; 7(3):584-604. PubMed ID: 25875246
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Bispecific monoclonal antibodies for targeted immunotherapy of solid tumors: Recent advances and clinical trials.
    Hosseini SS; Khalili S; Baradaran B; Bidar N; Shahbazi MA; Mosafer J; Hashemzaei M; Mokhtarzadeh A; Hamblin MR
    Int J Biol Macromol; 2021 Jan; 167():1030-1047. PubMed ID: 33197478
    [TBL] [Abstract][Full Text] [Related]  

  • 31. MUC1-specific targeting immunotherapy with bispecific antibodies: inhibition of xenografted human bile duct carcinoma growth.
    Katayose Y; Kudo T; Suzuki M; Shinoda M; Saijyo S; Sakurai N; Saeki H; Fukuhara K; Imai K; Matsuno S
    Cancer Res; 1996 Sep; 56(18):4205-12. PubMed ID: 8797593
    [TBL] [Abstract][Full Text] [Related]  

  • 32. The efficacy of CD3 x CD19 bispecific monoclonal antibody (BsAb) in a clonogenic assay: the effect of repeated addition of BsAb and interleukin-2.
    Haagen IA; Geerars AJ; de Lau WB; Bast BJ; de Gast BC
    Blood; 1995 Jun; 85(11):3208-12. PubMed ID: 7538821
    [TBL] [Abstract][Full Text] [Related]  

  • 33. A Modeling Framework to Characterize Cytokine Release upon T-Cell-Engaging Bispecific Antibody Treatment: Methodology and Opportunities.
    Chen X; Kamperschroer C; Wong G; Xuan D
    Clin Transl Sci; 2019 Nov; 12(6):600-608. PubMed ID: 31268236
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Simultaneous Inhibition of PD-1 and Stimulation of CD40 Signaling Pathways by Anti-PD-L1/CD40L Bispecific Fusion Protein Synergistically Activate Target and Effector Cells.
    Pandey MS; Wang C; Umlauf S; Lin S
    Int J Mol Sci; 2021 Oct; 22(21):. PubMed ID: 34768776
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Structural design of disialoganglioside GD2 and CD3-bispecific antibodies to redirect T cells for tumor therapy.
    Cheng M; Ahmed M; Xu H; Cheung NK
    Int J Cancer; 2015 Jan; 136(2):476-86. PubMed ID: 24895182
    [TBL] [Abstract][Full Text] [Related]  

  • 36. An Fc-inert PD-L1×4-1BB bispecific antibody mediates potent anti-tumor immunity in mice by combining checkpoint inhibition and conditional 4-1BB co-stimulation.
    Muik A; Altintas I; Gieseke F; Schoedel KB; Burm SM; Toker A; Salcedo TW; Verzijl D; Eisel D; Grunwitz C; Kranz LM; Vormehr M; Satijn DPE; Diken M; Kreiter S; Sasser K; Ahmadi T; Türeci Ö; Breij ECW; Jure-Kunkel M; Sahin U
    Oncoimmunology; 2022; 11(1):2030135. PubMed ID: 35186440
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Development and characterization of NILK-2301, a novel CEACAM5xCD3 κλ bispecific antibody for immunotherapy of CEACAM5-expressing cancers.
    Seckinger A; Majocchi S; Moine V; Nouveau L; Ngoc H; Daubeuf B; Ravn U; Pleche N; Calloud S; Broyer L; Cons L; Lesnier A; Chatel L; Papaioannou A; Salgado-Pires S; Krämer S; Gockel I; Lordick F; Masternak K; Poitevin Y; Magistrelli G; Malinge P; Shang L; Kallendrusch S; Strein K; Hose D
    J Hematol Oncol; 2023 Dec; 16(1):117. PubMed ID: 38087365
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Bispecific Antibodies for Non-Hodgkin Lymphoma Treatment.
    Bock AM; Nowakowski GS; Wang Y
    Curr Treat Options Oncol; 2022 Feb; 23(2):155-170. PubMed ID: 35182296
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Suppression of c-Met-Overexpressing Tumors by a Novel c-Met/CD3 Bispecific Antibody.
    Huang L; Xie K; Li H; Wang R; Xu X; Chen K; Gu H; Fang J
    Drug Des Devel Ther; 2020; 14():3201-3214. PubMed ID: 32982167
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Invariant NKT cells dictate antitumor immunity elicited by a bispecific antibody cotargeting CD3 and BCMA.
    Casey M; Tu C; Harrison SJ; Nakamura K
    Blood Adv; 2022 Sep; 6(17):5165-5170. PubMed ID: 35830292
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 15.